NPNicholas Alexander Pickersgill

Nicholas Alexander Pickersgill

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nicholas Alexander Pickersgill has a total of 93 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Development and Validation of a Patient-Centered Scale to Evaluate Decision Aid Usability and Information Overload

    by Nicholas A. Pickersgill, Amy L. Tin, Sunny Nalavenkata, Mia D. Austria, Kristina Stevanovic, Oskar Bergengren, Jason P. Gonsky, Jada G. Hamilton, Jennifer L. Hay, Andrew J. Vickers, et al.

    Introduction: Decision aids aim to improve the quality of and satisfaction with decision making. Few scales exist that directly evaluate decision aids from the patient’s perspective, particularly with respect to information overload. Methods: We developed a Decision Aid Evaluation Scale with domains assessing acceptability, satisfaction, cognitive load, and helpfulness for decision making. Cognitive interviews and iterative testing were performed. Convergent and discriminant construct validity were assessed by comparing the novel scale with domains from the validated Decisional Conflict Scale (DCS; values clarity, uncertainty, feeling informed subscales). Internal consistency was measured using Cronbach’s alpha. The final scale consisted of Likert-type scale items assessing information amount, values clarity, ease of use, cognitive effort required, nervousness, and overall helpfulness. Participants (any sex or gender, aged 40–60 y) completed the scale after viewing a cancer screening decision aid within a hypothetical screening decision scenario. Results: We surveyed 1,249 participants; 778 completed the Decision Aid Evaluation Scale. As hypothesized, a larger proportion of participants who reported low cognitive load had higher DCS values clarity subscale scores than those with high cognitive load ( P = 0.003). Participants who found the decision aid helpful had significantly higher DCS values clarity ( P < 0.001), informed ( P = 0.004), and certainty subscale scores ( P < 0.001). Scores on the acceptability questions were higher among those who found the decision aid helpful ( P < 0.001), except for questions related to “length,” “relatability of photo,” and “photo helped make decision.” Participants reporting nervousness had lower DCS certainty subscale scores ( P < 0.001). Cronbach’s alpha for the acceptability and satisfaction domains were 0.74 and 0.75, respectively, indicating internal consistency. Conclusions: We developed a patient-centered scale that captures users’ perceptions of decision aid usability and information overload. The scale demonstrated acceptable construct validity and internal consistency, supporting its use in evaluating decision aids from the patient perspective.

  • Open Access

    Total Gleason Pattern 4 Length Outperforms Grade Group and Clinical Models in Predicting Oncologic Outcomes in Grade Group 2-4 Prostate Cancer

    by Nicholas A. Pickersgill, Sean A. Fletcher, Nate Aiken, Melissa J. Assel, Nicole Liso, Victor E. Reuter, Andrew J. Vickers, Behfar Ehdaie, Samson W. Fine

    Background and Objective: Risk stratification in localized prostate cancer relies primarily on Grade group (GG). In GG2-4 disease, risk assignment depends on the proportions of pattern 3 and pattern 4. We hypothesized that total pattern 4 length on biopsy would better predict oncologic outcome than GG, percent pattern 4, and multivariable models (“nomograms”) based on clinical variables. Methods: We identified 2499 patients with GG2-4 prostate cancer on biopsy who underwent radical prostatectomy. Discrimination for predictors was calculated for adverse pathologic stage (seminal vesicle invasion or lymph node invasion) and biochemical recurrence (BCR). Key Findings and Limitations: Total pattern 4 length for the case demonstrated the highest discrimination for adverse pathologic stage in comparison with GG (AUC 0.779 vs 0.658; pWhat does the study add? : Patients with Grade group 2-4 prostate cancer constitute both the largest group and the one in which treatment decision-making is most difficult. For such patients, total length of Gleason pattern 4 on biopsy predicted oncologic outcomes better than Grade group or multivariable models including the standard predictors of stage, grade, PSA, PI-RADS and number of positive cores. Neither mm of pattern 3 nor the standard predictors add discrimination once total length of pattern 4 is known. Patient Summary : Treatment decisions in prostate cancer are often determined by the ratio of pattern 4 to pattern 3 disease. We showed that, in GG2-4 disease, using the total amount of pattern 4 for the case better predicts risk and therefore provides a better basis for treatment decisions. Take Home Message: In Grade group 2-4 prostate cancer, total Gleason pattern 4 length for the case is a stronger predictor of adverse pathologic stage and biochemical recurrence than Grade group and other standard clinical variables. Further research is warranted to determine the optimal method for quantifying pattern 4 before incorporation into risk stratification algorithms.


  • Open Access

    Meta-analysis reveals differences in somatic alterations by genetic ancestry across common cancers

    by Setor Amuzu, Amy X. Xie, Xuechun Bai, Kelly R. Pekala, Nicholas A. Pickersgill, David Ma, Tomin Perea-Chamblee, Kanika Arora, Walid K. Chatila, Andriy Derkach, et al.

    Genetic similarity of populations (or genetic ancestry) is associated with differences in somatic alterations in cancers. We meta-analyze two targeted panel sequencing cohorts with 275,605 samples from 14 cancer types. Here we find a recurrent depletion of TERT promoter mutations in patients of African and East Asian ancestry across multiple cancers. Several clinically actionable alterations, such as ERBB2 mutations in lung adenocarcinoma and MET mutations in papillary renal cell carcinoma, occur at a higher frequency in patients of non-European ancestry. Furthermore, in both cohorts, we show depletions in total driver alterations in non-European ancestries in multiple cancer types, potentially reflecting biases in current panel-based testing that prioritize established targets derived from predominantly patients of European ancestry. Our study highlights a need to increase population diversity in genomic studies to find new drivers and enhance precision oncology interventions for all populations.


  • Diagnostic accuracy of biparametric vs. multiparametric MRI for clinically significant prostate cancer

    by Nicholas A. Pickersgill, Alex L. Shiang, Joel M. Vetter, John Sheng, Kainen L. Utt, Huaping Jing, R. Cody Weimholt, Sheng-Kwei Song, Joseph E. Ippolito, Eric H. Kim

    Background Multiparametric magnetic resonance imaging (MRI) is the most widely used approach for prostate MRI. While biparametric MRI (BP-MRI) involves shorter acquisition time and decreased cost, its diagnostic accuracy compared to multiparametric MRI (MP-MRI) is not well known. We aim to compare the detection of clinically significant prostate cancer with BP-MRI and MP-MRI prior to biopsy. Methods We retrospectively analyzed men who underwent BP-MRI or MP-MRI between January 2019 and December 2022, interpreted by a single expert radiologist. All patients underwent systematic and targeted transperineal prostate biopsy. Diagnostic performance was compared using Receiver operating characteristic curves, test performance parameters, and assessed net benefit with decision curve analysis, using biopsy with Grade Group ≥ 2 disease as the reference standard. Results Among 310 patients (192 MP-MRI, 118 BP-MRI), suspicious lesions were identified in 63% vs. 47%, respectively. Area under the curve values were 0.81 for MP-MRI and 0.88 for BP-MRI (p = 0.4). At PI-RADS ≥ 4, BP-MRI sensitivity/specificity were 71%/79% vs. 79%/55% for MP-MRI. At PI-RADS ≥ 3, sensitivities were similar but specificities were lower for both. Decision curve analysis showed similar net benefit for both protocols across clinically relevant thresholds. In multivariable analysis adjusting for age and PI-RADS, MRI type was not associated with clinically significant cancer detection (OR 0.88, 95% CI 0.53–1.45). Conclusions Biparametric and multiparametric MRI protocols demonstrate comparable accuracy in the detection of clinically significant prostate cancer, suggesting that dynamic contrast enhancement offers limited clinical benefit. Biparametric MRI should be considered the standard for pre-biopsy imaging in patients with suspected prostate cancer.


  • Intermediate-Term Oncologic Outcomes of Partial Nephrectomy vs Cryoablation in Renal Tumors > 3 cm: A Propensity Score–Matched Analysis

    by Nicholas A. Pickersgill, Joel M. Vetter, Dylan J. Mittauer, Lauren Elson, Joshua K. Palka, Nimrod S. Barashi, Eric H. Kim, Ramakrishna Venkatesh, Sam B. Bhayani, R. Sherburne Figenshau

    Cryoablation (CA) and partial nephrectomy (PN) are effective nephron-sparing treatments for small renal masses. While guidelines list thermal ablation as an option for tumors 3 cm. Patients treated with PN or CA for cT1/cT2, N0M0 renal masses >3 cm between 2006 and 2016 were identified. Propensity score matching was performed in a 1:2 ratio for patients undergoing CA or PN based on age, BMI, Charlson Comorbidity Index (CCI), tumor size, and nephrometry score. Disease-free survival (DFS), metastasis-free survival (MFS), cancer-specific survival (CSS), and overall survival (OS) were estimated using Kaplan-Meier analysis. One hundred thirteen and 57 patients underwent PN and CA with median follow-up of 4.5 and 3.8 years, respectively. CA was associated with significantly lower 5-year DFS compared to PN (75% vs. 94%, p3 cm. CA is a viable option for well-selected patients with comorbidities or high surgical risk, when combined with salvage ablation as indicated.


  • Correlation of Prostate High-Resolution Microultrasound With Multiparametric Magnetic Resonance Imaging

    by Nicholas A. Pickersgill, Muhammad Hassan Alkazemi, Adam Ostergar, Karan Joseph, Joel M. Vetter, Nimrod S. Barashi, Eric H. Kim, Gerald L. Andriole, Arjun Sivaraman


  • Open Access

    Preoperative prostate magnetic resonance imaging does not impact surgical outcomes of radical prostatectomy

    by Christopher K. Bozorgmehr, Johnny Wang, James T. Gross, Nicholas A. Pickersgill, Joel M. Vetter, Joseph E. Ippolito, Eric H. Kim

    Objective: We reviewed our institutional experience of radical prostatectomy with and without preoperative multiparametric magnetic resonance imaging (mpMRI) to assess the impact of preoperative prostate mpMRI on surgical outcomes of radical prostatectomy. Methods: We identified patients at our institution who underwent radical prostatectomy for prostate cancer (PCa) between January 2012 and December 2017 (n = 1044). Using propensity scoring analysis, patients who underwent preoperative mpMRI (n = 285) were matched 1:1 to patients who did not receive preoperative mpMRI (n = 285). Multivariable regression analysis was performed to identify factors predictive of operative time, estimated blood loss (EBL), lymph node yield, rates of complications within 30 days, and positive surgical margin (PSM). Results: There were no significant differences in operative time, EBL, PSM, lymph node yield, or complication rates between the two cohorts. Multivariable analysis demonstrated that preoperative mpMRI was not predictive of the measured perioperative outcomes. Significant comorbidity (Charlson Comorbidity Index ≥3) was the sole predictor of perioperative complications (P = 0.015). Increasing biopsy Gleason score predicted increased lymph node yield (P < 0.001). The probability of PSM was associated with increasing preoperative prostate-specific antigen (odds ratio 1.036, P = 0.009). Body mass index was a predictor of operative time (P = 0.016) and EBL (P = 0.001). Conclusions: Although preoperative mpMRI has an important role in the diagnosis and staging of PCa, it does not impact perioperative radical prostatectomy outcomes. Our findings do not support the routine use of preoperative mpMRI for surgical planning in patients already diagnosed with clinically localized PCa.


  • Single-port vs multi-port robot-assisted renal surgery: analysis of perioperative outcomes for excision of high and low complexity renal masses

    by James M. Berry, Hayden Hill, Joel M. Vetter, Sam B. Bhayani, Grant M. Henning, Nicholas A. Pickersgill, Arjun Sivaraman, R. Sherburne Figenshau, Eric H. Kim

    There is emerging but limited data assessing single-port (SP) robot-assisted surgery as an alternative to multi-port (MP) platforms. We compared perioperative outcomes between SP and MP robot-assisted approaches for excision of high and low complexity renal masses. Retrospective chart review was performed for patients undergoing robot-assisted partial or radical nephrectomy using the SP surgical system (n = 23) at our institution between November 2019 and November 2021. Renal masses were categorized as high complexity (7+) or low complexity (4–6) using the R.E.N.A.L. nephrometry scoring system. Adjusting for baseline characteristics, patients were matched using a prospectively maintained MP database in a 2:1 (MP:SP) ratio. For high complexity tumors (n = 12), SP surgery was associated with a significantly longer operative time compared to MP (248.4 vs 188.1 min, p = 0.02) but a significantly shorter length of stay (1.9 vs 2.8 days, p = 0.02). For low complexity tumors (n = 11), operative time (177.7 vs 161.4 min, p = 0.53), estimated blood loss (69.6.0 vs 142.0 mL, p = 0.62), and length of stay (1.6 vs 1.8 days, p = 0.528) were comparable between SP and MP approaches. Increasing nephrometry score was associated with a greater relative increase in operative time for SP compared to MP renal surgery (p = 0.07) using best of fit linear modeling. SP robot-assisted partial and radical nephrectomy is safe and feasible for low complexity renal masses. For high complexity renal masses, the SP system is associated with a significantly longer operative time compared to the MP technique. Careful consideration should be given when selecting patients for SP robot-assisted kidney surgery.


  • Post-chemotherapy Laparoscopic Retroperitoneal Lymph Node Dissection for Mixed Malignant Germ Cell Testicular Tumors

    by Nicholas A. Pickersgill, Neel S. Raval, Eric H. Kim, River G. Black, Kefu Du, R. Sherburne Figenshau